We provide proof-of-concept evidence that pretreatment with DHODH inhibitors can improve the efficacy of ICB in a highly aggressive and ICB-refractory mouse melanoma model (Figure 5, Figure 5—figure supplement 1). The gene discussed is DHODH; the disease is melanoma.